BioCryst Pharmaceuticals Inc (BCRX)
7.485
+0.18
(+2.53%)
USD |
NASDAQ |
Nov 21, 16:00
7.485
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Revenue (Quarterly): 117.08M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 117.08M |
June 30, 2024 | 109.33M |
March 31, 2024 | 92.76M |
December 31, 2023 | 93.40M |
September 30, 2023 | 86.74M |
June 30, 2023 | 82.49M |
March 31, 2023 | 68.78M |
December 31, 2022 | 79.54M |
September 30, 2022 | 75.83M |
June 30, 2022 | 65.53M |
March 31, 2022 | 49.92M |
December 31, 2021 | 47.16M |
September 30, 2021 | 40.99M |
June 30, 2021 | 49.96M |
March 31, 2021 | 19.06M |
December 31, 2020 | 4.016M |
September 30, 2020 | 6.102M |
June 30, 2020 | 2.871M |
March 31, 2020 | 4.823M |
December 31, 2019 | 39.72M |
September 30, 2019 | 1.775M |
June 30, 2019 | 1.448M |
March 31, 2019 | 5.887M |
December 31, 2018 | 2.729M |
September 30, 2018 | 1.454M |
Date | Value |
---|---|
June 30, 2018 | 12.49M |
March 31, 2018 | 3.976M |
December 31, 2017 | 3.89M |
September 30, 2017 | 8.76M |
June 30, 2017 | 3.099M |
March 31, 2017 | 9.437M |
December 31, 2016 | 8.983M |
September 30, 2016 | 7.763M |
June 30, 2016 | 4.787M |
March 31, 2016 | 4.82M |
December 31, 2015 | 4.602M |
September 30, 2015 | 10.99M |
June 30, 2015 | 25.84M |
March 31, 2015 | 6.826M |
December 31, 2014 | 5.446M |
September 30, 2014 | 3.238M |
June 30, 2014 | 1.466M |
March 31, 2014 | 3.458M |
December 31, 2013 | 10.57M |
September 30, 2013 | 2.389M |
June 30, 2013 | 0.821M |
March 31, 2013 | 3.554M |
December 31, 2012 | 4.101M |
September 30, 2012 | 5.761M |
June 30, 2012 | 4.21M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.871M
Minimum
Jun 2020
117.08M
Maximum
Sep 2024
56.81M
Average
57.75M
Median
Revenue (Quarterly) Benchmarks
AIM ImmunoTech Inc | 0.035M |
Perspective Therapeutics Inc | -- |
Protalix BioTherapeutics Inc | 17.96M |
Electromed Inc | 14.67M |
Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -14.03M |
Total Expenses (Quarterly) | 109.39M |
EPS Diluted (Quarterly) | -0.07 |
Enterprise Value | 1.978B |
Gross Profit Margin (Quarterly) | 97.24% |
Profit Margin (Quarterly) | -11.99% |
Earnings Yield | -8.15% |
Normalized Earnings Yield | -8.124 |